Healthcare / BiotechnologyNasdaqCM
$12.93
+0.37 (+2.95%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-13.3M · quality 67.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$148M
P/E
N/A
•EV/EBITDA
N/A
•ROE
249.4%
↑Gross Margin
N/A
•Debt/Equity
-0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-31614.3%
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $42000.0 · net income $-20.7M · FCF $-13.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $42000.00 | $42000.00 | $2.3M | — | — |
| Net Income | $-20.7M | $-20.7M | $-26.8M | $-20.5M | $-25.0M |
| EBITDA | $-13.3M | $-13.3M | $-26.6M | $-22.3M | $-23.5M |
| EPS | -18.90 | -18.90 | — | -56.15 | -93.05 |
| Operating Margin | -33850.0% | -33850.0% | -1233.2% | — | — |
| Net Margin | -49290.5% | -49290.5% | -1160.2% | — | — |
| Balance Sheet | |||||
| Debt/Equity | -0.05 | -0.05 | -0.06 | 0.15 | 0.10 |
| Current Ratio | 2.87 | 2.87 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-13.3M | $-13.3M | $-9.6M | $-15.2M | $-22.8M |
| Returns | |||||
| ROE | 249.4% | 249.4% | 267.3% | -169.8% | -136.9% |
| Valuation | |||||
| P/B | — | — | — | 8.26 | 14.75 |
| Growth & Yield | |||||
| Revenue Growth | -98.2% | -98.2% | — | — | — |
| EPS Growth | — | — | — | 39.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+242.1%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → -18.90
Residual
+242.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.